Upadacitinib meets primary endpoint in phase 3 induction study in ulcerative colitis

In the second of two phase 3 induction studies, upadacitinib (45 mg once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score). Results showed 33% of patients receiving upadacitinib achieved clinical remission at week 8 vs 4 % receiving placebo (p<0.001).

Source:

Biospace Inc.